Chunmin Ge1, Chrystelle L Vilfranc1, Lixiao Che1, Raj K Pandita2, Shashank Hambarde2, Paul R Andreassen3, Liang Niu4, Olugbenga Olowokure5, Shimul Shah6, Susan E Waltz1, Lee Zou7, Jiang Wang8, Tej K Pandita2, Chunying Du1. 1. Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH. 2. Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX. 3. Division of Experimental Hematology and Cancer Biology, Cincinnati Children Hospital Medical Center, Cincinnati, OH. 4. Department of Environmental Health, University of Cincinnati, Cincinnati, OH. 5. Department of Internal Medicine, University of Cincinnati, Cincinnati, OH. 6. University of Cincinnati College of Medicine, University of Cincinnati, Cincinnati, OH. 7. Department of Pathology, Massachusetts General Hospital Cancer Center; Harvard Medical School, Charlestown, MA. 8. Department of Pathology, University of Cincinnati, Cincinnati, OH.
Abstract
Replication fork stability during DNA replication is vital for maintenance of genomic stability and suppression of cancer development in mammals. ATR (ataxia-telangiectasia mutated [ATM] and RAD3-related) is a master regulatory kinase that activates the replication stress response to overcome replication barriers. Although many downstream effectors of ATR have been established, the upstream regulators of ATR and the effect of such regulation on liver cancer remain unclear. The ubiquitin conjugase BRUCE (BIR Repeat containing Ubiquitin-Conjugating Enzyme) is a guardian of chromosome integrity and activator of ATM signaling, which promotes DNA double-strand break repair through homologous recombination. Here we demonstrate the functions for BRUCE in ATR activation in vitro and liver tumor suppression in vivo. BRUCE is recruited to induced DNA damage sites. Depletion of BRUCE inhibited multiple ATR-dependent signaling events during replication stress, including activation of ATR itself, phosphorylation of its downstream targets CHK1 and RPA, and the mono-ubiquitination of FANCD2. Consequently, BRUCE deficiency resulted in stalled DNA replication forks and increased firing of new replication origins. The in vivo impact of BRUCE loss on liver tumorigenesis was determined using the hepatocellular carcinoma model induced by genotoxin diethylnitrosamine. Liver-specific knockout of murine Bruce impaired ATR activation and exacerbated inflammation, fibrosis and hepatocellular carcinoma, which exhibited a trabecular architecture, closely resembling human hepatocellular carcinoma (HCC). In humans, the clinical relevance of BRUCE down-regulation in liver disease was found in hepatitis, cirrhosis, and HCC specimens, and deleterious somatic mutations of the Bruce gene was found in human hepatocellular carcinoma in the Cancer Genome Atlas database. Conclusion: These findings establish a BRUCE-ATR signaling axis in accurate DNA replication and suppression of liver cancer in mice and humans and provides a clinically relevant HCC mouse model.
Replication fork stability during DNA replication is vital for maintenance of genomic stability and suppression of cancer development in mammals. ATR (ataxia-telangiectasia mutated [ATM] and RAD3-related) is a master regulatory kinase that activates the replication stress response to overcome replication barriers. Although many downstream effectors of ATR have been established, the upstream regulators of ATR and the effect of such regulation on liver cancer remain unclear. The ubiquitin conjugase BRUCE (BIR Repeat containing Ubiquitin-Conjugating Enzyme) is a guardian of chromosome integrity and activator of ATM signaling, which promotes DNA double-strand break repair through homologous recombination. Here we demonstrate the functions for BRUCE in ATR activation in vitro and liver tumor suppression in vivo. BRUCE is recruited to induced DNA damage sites. Depletion of BRUCE inhibited multiple ATR-dependent signaling events during replication stress, including activation of ATR itself, phosphorylation of its downstream targets CHK1 and RPA, and the mono-ubiquitination of FANCD2. Consequently, BRUCE deficiency resulted in stalled DNA replication forks and increased firing of new replication origins. The in vivo impact of BRUCE loss on liver tumorigenesis was determined using the hepatocellular carcinoma model induced by genotoxin diethylnitrosamine. Liver-specific knockout of murineBruce impaired ATR activation and exacerbated inflammation, fibrosis and hepatocellular carcinoma, which exhibited a trabecular architecture, closely resembling humanhepatocellular carcinoma (HCC). In humans, the clinical relevance of BRUCE down-regulation in liver disease was found in hepatitis, cirrhosis, and HCC specimens, and deleterious somatic mutations of the Bruce gene was found in humanhepatocellular carcinoma in the Cancer Genome Atlas database. Conclusion: These findings establish a BRUCE-ATR signaling axis in accurate DNA replication and suppression of liver cancer in mice and humans and provides a clinically relevant HCCmouse model.
Authors: I Garcia-Higuera; T Taniguchi; S Ganesan; M S Meyn; C Timmers; J Hejna; M Grompe; A D D'Andrea Journal: Mol Cell Date: 2001-02 Impact factor: 17.970
Authors: Niall G Howlett; Toshiyasu Taniguchi; Sandra G Durkin; Alan D D'Andrea; Thomas W Glover Journal: Hum Mol Genet Date: 2005-01-20 Impact factor: 6.150
Authors: Jinyu Ren; Mingan Shi; Renshui Liu; Qi-Heng Yang; Teri Johnson; William C Skarnes; Chunying Du Journal: Proc Natl Acad Sci U S A Date: 2005-01-07 Impact factor: 11.205
Authors: Lixiao Che; Kris G Alavattam; Peter J Stambrook; Satoshi H Namekawa; Chunying Du Journal: Cell Death Differ Date: 2020-03-05 Impact factor: 15.828
Authors: Kaihua Zhong; Dong Chen; Zhiming Wu; Xiaohong Wang; Bin Pan; Nanhui Chen; Weifeng Zhong Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2020-11-30